drugset / Trial / NCT00630786

Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study

NCT00630786

Phase 1/2 Completed 53 enrolled Amgen
NaSingle-groupOpen-labelTreatment

Summary

This is an exploratory phase 1b/2, global, multicenter, single-arm, 2-part (phase 1b and 2) study of conatumumab in combination with panitumumab in patients with Metastatic Colorectal Cancer.

Timeline

Start
2008-01
Primary completion
2009-05
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Conatumumab Monoclonal antibody 10 mg/kg Intravenous
Subject Panitumumab Monoclonal antibody 6 mg/kg Intravenous